Exploring the Intersection of Sarcoidosis and Cardiac Arrhythmias

Year 2024, Volume: 6 Issue: 4, 135 - 143, 29.10.2024

Himanshi Banker , Saurabh Sujanyal Sai Ganesh Upputuri Sai Gautham Kanagala Jayesh Valecha Rohit Jain

https://doi.org/10.46310/tjim.1477470

Abstract

Sarcoidosis is a multi-organ granulomatous disease of uncertain origin, characterized by the formation of non-necrotizing granulomas in various organs, including the heart. Cardiac involvement in sarcoidosis is rare, with approximately 5% of sarcoidosis patients developing clinically apparent cardiac disease, which is associated with significant morbidity and mortality. Genetically predisposed individuals develop granuloma in myocardium musculature, leading to aberrant conduction of cardiac impulses and the development of various arrhythmias. Common arrhythmias range from atrial fibrillation to ventricular tachycardia and can lead to sudden cardiac death because of ventricular fibrillation. The diagnostic challenge results from high specificity but rather limited sensitivity of endomyocardial biopsy, which is the gold standard diagnostic test, making advanced imaging techniques, such as cardiac magnetic resonance imaging and fluorine-18 fluorodeoxyglucose positron emission tomography, crucial for early detection. Management involves a complex approach with immunosuppression, antiarrhythmic medications, and catheter ablation, often supplemented by implantable cardioverter-defibrillators to prevent sudden cardiac death. In cardiac sarcoidosis, ventricular arrhythmias are common and cause high mortality. Timely intervention and management are crucial for a better prognosis. The disease's growing prevalence requires further research on refining early detection techniques and developing efficient treatment strategies for these high-risk patients. This review focuses on the etiopathogenesis of arrhythmias in cardiac sarcoidosis, diagnosis, and effective management strategies.

Keywords

Sarcoidosis, Granulomatous disorder, Cardiac arrhythmias, Ventricular tachycardia, atrial fibrillation, AV block.

References

• Sawahata M, Sugiyama Y, Nakamura Y, Nakayama M, Mato N, Yamasawa H, Bando M. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. Respir Med. 2015 Feb;109(2):272-8. doi: 10.1016/j.rmed.2014.12.012.
• Korsten P, Sweiss NJ, Baughman RP. Sarcoidosis. In: Firestein GS, Budd RC, Gabriel SE, Koretzky GA, McInnes IB, O’Dell JR, eds. Firestein & Kelley’s Textbook of Rheumatology. 11th ed. Elsevier: 2020:2088-104.
• Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006 Feb;92(2):282-8. doi: 10.1136/hrt.2005.080481.
• Sève P, Pacheco Y, Durupt F, Jamilloux Y, Gerfaud-Valentin M, Isaac S, Boussel L, Calender A, Androdias G, Valeyre D, El Jammal T. Sarcoidosis: A clinical overview from symptoms to diagnosis. Cells. 2021 Mar 31;10(4):766. doi: 10.3390/cells10040766.
• Mathai SV, Patel S, Jorde UP, Rochlani Y. Epidemiology, pathogenesis, and diagnosis of cardiac sarcoidosis. Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):78-93. doi: 10.14797/mdcvj.1057.
• Desai R, Kakumani K, Fong HK, Shah B, Zahid D, Zalavadia D, Doshi R, Goyal H. The burden of cardiac arrhythmias in sarcoidosis: a population-based inpatient analysis. Ann Transl Med. 2018 Sep;6(17):330. doi: 10.21037/atm.2018.07.33.
• Felker GM, Mann DL. Heart Failure: A Companion to Braunwald’s Heart Disease. 4th ed. Elsevier; 2019.
• Yada H, Soejima K. Management of arrhythmias associated with cardiac sarcoidosis. Korean Circ J. 2019 Feb;49(2):119-133. doi: 10.4070/kcj.2018.0432.
• Ipek E, Demirelli S, Ermis E, Inci S. Sarcoidosis and the heart: A review of the literature. Intractable Rare Dis Res. 2015 Nov;4(4):170-80. doi: 10.5582/irdr.2015.01023.
• Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol. 2016 Jul 26;68(4):411-21. doi: 10.1016/j.jacc.2016.03.605.
• Shah HH, Zehra SA, Shahrukh A, Waseem R, Hussain T, Hussain MS, Batool F, Jaffer M. Cardiac sarcoidosis: a comprehensive review of risk factors, pathogenesis, diagnosis, clinical manifestations, and treatment strategies. Front Cardiovasc Med. 2023 May 19:10:1156474. doi: 10.3389/fcvm.2023.1156474.
• Gilotra N, Okada D, Sharma A, Chrispin J. Management of cardiac sarcoidosis in 2020. Arrhythm Electrophysiol Rev. 2020 Dec;9(4):182-8. doi: 10.15420/aer.2020.09.
• Rossides M, Darlington P, Kullberg S, Arkema EV. Sarcoidosis: Epidemiology and clinical insights. J Intern Med. 2023 Jun;293(6):668-80. doi: 10.1111/joim.13629.
• Mankad P, Mitchell B, Birnie D, Kron J. Cardiac Sarcoidosis. Curr Cardiol Rep. 2019 Nov 25;21(12):152. doi: 10.1007/s11886-019-1238-1.
• Birnie D, Beanlands RSB, Nery P, Aaron SD, Culver DA, DeKemp RA, Gula L, Ha A, Healey JS, Inoue Y, Judson MA, Juneau D, Kusano K, Quinn R, Rivard L, Toma M, Varnava A, Wells G, Wickremasinghe M, Kron J. Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). Am Heart J. 2020 Feb;220:246-52. doi: 10.1016/j.ahj.2019.10.003.
• Moller DR, Rybicki BA, Hamzeh NY, Montgomery CG, Chen ES, Drake W, Fontenot AP. Genetic, immunologic, and environmental basis of sarcoidosis. Ann Am Thorac Soc. 2017 Dec;14(Supplement_6):S429-36. doi: 10.1513/AnnalsATS.201707-565OT.
• Strambu IR. Challenges of cardiac sarcoidosis. Frontiers in Medicine. 2023; 10. doi: 10.3389/fmed.2023.999066.
• Jain R, Yadav D, Puranik N, Guleria R, Jin JO. Sarcoidosis: Causes, diagnosis, clinical features, and treatments. J Clin Med. 2020 Apr 10;9(4):1081. doi: 10.3390/jcm9041081.
• Shigemitsu H, Patel HV, Schreiber MP. Extrapulmonary sarcoidosis. In: Judson MA, ed, Pulmonary Sarcoidosis: A Guide for the Practicing Clinician. New York, NY: Humana Press; 2014:149-86.
• Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, Prystowsky S. Cardiac sarcoidosis. Am Heart J. 2009 Jan;157(1):9-21. doi: 10.1016/j.ahj.2008.09.009.
• Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014 Jul;11(7):1305-23. doi: 10.1016/j.hrthm.2014.03.043.
• Rosenfeld LE, Chung MK, Harding CV, Spagnolo P, Grunewald J, Appelbaum J, Sauer WH, Culver DA, Joglar JA, Lin BA, Jellis CL, Dickfeld TM, Kwon DH, Miller EJ, Cremer PC, Bogun F, Kron J, Bock A, Mehta D, Leis P, Siontis KC, Kaufman ES, Crawford T, Zimetbaum P, Zishiri ET, Singh JP, Ellenbogen KA, Chrispin J, Quadri S, Vincent LL, Patton KK, Kalbfleish S, Callahan TD, Murgatroyd F, Judson MA, Birnie D, Okada DR, Maulion C, Bhat P, Bellumkonda L, Blankstein R, Cheng RK, Farr MA, Estep JD. Arrhythmias in cardiac sarcoidosis bench to bedside: A case-based review. Circ Arrhythm Electrophysiol. 2021 Feb;14(2):e009203. doi: 10.1161/CIRCEP.120.009203.
• Joukar S. A comparative review on heart ion channels, action potentials and electrocardiogram in rodents and human: extrapolation of experimental insights to clinic. Lab Anim Res. 2021 Sep 8;37(1):25. doi: 10.1186/s42826-021-00102-3.
• Viles-Gonzalez JF, Pastori L, Fischer A, Wisnivesky JP, Goldman MG, Mehta D. Supraventricular arrhythmias in patients with cardiac sarcoidosis. Chest. 2013 Apr;143(4):1085-90. doi: 10.1378/chest.11-3214.
• Viwe M, Nery P, Birnie DH. Management of ventricular tachycardia in patients with cardiac sarcoidosis. Heart Rhythm O2. 2021 Jul 20;2(4):412-22. doi: 10.1016/j.hroo.2021.07.005.
• Goyal A, Basit H, Bhyan P, Zeltser R. Reentry arrhythmia. Updated 2023 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK537089/.
• Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM, Burke MC, Garrity ER, Hogarth DK, Archer SL, Sweiss NJ, Beshai JF. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011 Nov;13(11):1231-7. doi: 10.1093/eurjhf/hfr099.
• Ribeiro Neto ML, Jellis CL, Joyce E, Callahan TD, Hachamovitch R, Culver DA. Update in cardiac sarcoidosis. Ann Am Thorac Soc. 2019 Nov;16(11):1341-1350. doi: 10.1513/AnnalsATS.201902-119CME.
• Terasaki F, Yoshinaga K. New Guidelines for Diagnosis of Cardiac Sarcoidosis in Japan. Ann Nucl Cardiol. 2017;3(1):42-5. doi: 10.17996/anc.17-00042.
• Ramirez R, Trivieri M, Fayad ZA, Ahmadi A, Narula J, Argulian E. Advanced imaging in cardiac sarcoidosis. J Nucl Med. 2019 Jul;60(7):892-8. doi: 10.2967/jnumed.119.228130.
• Chareonthaitawee P, Beanlands RS, Chen W, Dorbala S, Miller EJ, Murthy VL, Birnie DH, Chen ES, Cooper LT, Tung RH, White ES, Borges-Neto S, Di Carli MF, Gropler RJ, Ruddy TD, Schindler TH, Blankstein R. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol. 2017 Oct;24(5):1741-58. doi: 10.1007/s12350-017-0978-9.
• Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, Machac J, Teirstein A. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008 Jun;133(6):1426-35. doi: 10.1378/chest.07-2784.
• Lehtonen J, Uusitalo V, Pöyhönen P, Mäyränpää MI, Kupari M. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J. 2023 May 1;44(17):1495-510. doi: 10.1093/eurheartj/ehad067.
• Nagano N, Nagai T, Sugano Y, Morita Y, Asaumi Y, Aiba T, Kanzaki H, Kusano K, Noguchi T, Yasuda S, Ogawa H, Anzai T. Association between basal thinning of interventricular septum and adverse long-term clinical outcomes in patients with cardiac sarcoidosis. Circ J. 2015;79(7):1601-8. doi: 10.1253/circj.CJ-14-1217.
• Cain MA, Metzl MD, Patel AR, Addetia K, Spencer KT, Sweiss NJ, Beshai JF. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol. 2014 May 1;113(9):1556-60. doi: 10.1016/j.amjcard.2014.01.434.
• Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S, Bittencourt MS, Murthy VL, Kwong R, Di Carli MF, Blankstein R. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: A systematic review and meta-analysis. Circ Cardiovasc Imaging. 2016 Sep;9(9):e005001. doi: 10.1161/CIRCIMAGING.116.005001.
• Kim SJ, Pak K, Kim K. Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis. J Nucl Cardiol. 2020 Dec;27(6):2103-15. doi: 10.1007/s12350-018-01582-y.
• Cherrett C, Lee W, Bart N, Subbiah R. Management of the arrhythmic manifestations of cardiac sarcoidosis. Front Cardiovasc Med. 2023 May 25:10:1104947. doi: 10.3389/fcvm.2023.1104947.
• Li S, Wang H, Liu T, Li Q, Yang X, Xiong R, Lv Q, Du X, Dong J, Ma C. Adalimumab for the treatment of cardiac sarcoidosis with multiple arrhythmias. ESC Heart Fail. 2022 Dec;9(6):4325-9. doi: 10.1002/ehf2.14133.
• Harper LJ, McCarthy M, Ribeiro Neto ML, Hachamovitch R, Pearson K, Bonanno B, Shaia J, Brunken R, Joyce E, Culver DA. Infliximab for refractory cardiac sarcoidosis. Am J Cardiol. 2019 Nov 15;124(10):1630-5. doi: 10.1016/j.amjcard.2019.07.067.
• Tan JL, Jin C, Lee JZ, Gaughan J, Iwai S, Russo AM. Outcomes of catheter ablation for ventricular tachycardia in patients with sarcoidosis: Insights from the National Inpatient Sample database (2002-2018). J Cardiovasc Electrophysiol. 2022 Dec;33(12):2585-98. doi: 10.1111/jce.15708.
• Okada DR, Assis FR, Gilotra NA, Ha JS, Berger RD, Calkins H, Chrispin J, Mandal K, Tandri H. Cardiac sympathectomy for refractory ventricular arrhythmias in cardiac sarcoidosis. Heart Rhythm. 2019 Sep;16(9):1408-13. doi: 10.1016/j.hrthm.2019.02.025.
• De Bortoli A, Birnie DH. Diagnosis and treatment of cardiac sarcoidosis. Circ J. 2023 Mar 24;87(4):471-80. doi: 10.1253/circj.CJ-22-0671.